On October 15, SBP GROUP rose 3.1% in Regular Trading, trading at HK$5.33, with turnover of HK$132 million.
The move coincided with a broader advance in Hong Kong innovation drug names. Sector reports said healthcare stocks were rebounding from a cycle low as pipeline progress improved sentiment, while SBP GROUP-specific news highlighted that its unit Chia Tai Tianqing had a TQ-A3334 study selected as a late-breaking abstract for the AASLD annual meeting and that partnered product Bepirovirsen was included in two oral presentations and eight posters.
Recent company developments add context. In late September, the group announced a strategic biosimilars partnership with STADA for pembrolizumab biosimilar TQB3570 in Europe and other markets, with upfront consideration, potential milestone payments of up to 53 million euros, and double-digit profit sharing. The company had also reported first-half revenue of RMB19.44 billion, up 10.6%, and adjusted net profit of RMB3.34 billion, up 8.1%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
